Page 1361 - Williams Hematology ( PDFDrive )

1336 Part X: Malignant Myeloid Diseases Chapter 86: Primary Myelofibrosis 1337

271. Fayemi AO, Gerber MA, Cohen I, et al: Myeloid sarcoma. Cancer 32:253, 1973. 306. Thiele J, Holgado S, Choritz H, et al: Chronic megakaryocyte-granulocytic myelosis—
272. Yu JS, Greenway G, Resnick D: Myelofibrosis associated with prominent periosteal An electron microscope study including freeze-fracture. Virchows Arch A Pathol Anat
bone apposition. Clin Imaging 18:89, 1994. Histol 375:129, 1977.
273. Cervantes F, Alvarez-Larrán A, Arellano-Rodrigo E, et al: Frequency and risk factors 307. Mesa RA, Hanson CA, Rajkumar SV, et al: Evaluation and clinical correlations of bone
for thrombosis in idiopathic myelofibrosis: Analysis in a series of 155 patients from a marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 15:3374, 2000.
single institution. Leukemia 20:55, 2006. 308. Bauermeister DE. Quantitation of bone marrow reticulin—a normal range. Am J Clin
274. Buxhofer-Ausch V, Gisslinger H, Thiele J, et al: Leukocytosis as an important risk factor Pathol 56:24, 1971.
for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An interna- 309. Thiele J, Kvasnicka HM: Myelofibrosis—What’s in a name? Consensus on definition
tional study of 264 patients. Am J Hematol 87:669, 2012. and EUMNET grading. Pathobiology 74:89, 2007.
275. Barbui T, Carobbio A, Cervantes F, et al: Thrombosis in primary myelofibrosis: Inci- 310. Teman CJ, Wilson AR, Perkins SL, et al: Quantification of fibrosis and osteosclerosis in
dence and risk factors. Blood 115:778, 2010. myeloproliferative neoplasms: A computer-assisted image study. Leuk Res 34:871, 2010.
276. Smalberg JH, Arends LR, Valla DC, et al: Myeloproliferative neoplasms in Budd-Chiari 311. Hussein K, Van Dyke DL, Tefferi A: Conventional cytogenetics in myelofibrosis: Liter-
syndrome and portal vein thrombosis: A meta-analysis. Blood 120:4921, 2012. ature review and discussion. Eur J Haematol 82:329, 2009.
277. Barosi G, Cazzoli M, Frassoni F: Erythropoiesis in myelofibrosis with myeloid metapla- 312. Tam CS, Abruzzo LV, Lin KI, et al: The role of cytogenetic abnormalities as a prognostic
sia: Recognition of different classes of patients by erythrokinetics. Br J Haematol 48:263, marker in primary myelofibrosis: Applicability at the time of diagnosis and later during
1981. disease course. Blood 30:113, 2009.
278. Barosi G, Berzuinic C, Liberato LN, et al: A prognostic classification of myelofibrosis 313. Nakamura H, Sadamori N, Mine M, et al: Effects of short-term liquid culture of periph-
with myeloid metaplasia. Br J Haematol 70:397, 1988. eral blood mononuclear cells with recombinant human granulocyte or granulocyte-
279. Thiele J, Kvasnicka H-M, Werden C, et al: Idiopathic primary osteomyelofibrosis. Leuk macrophage colony-stimulating factor in cytogenetic studies of myelofibrosis with
Lymphoma 22:303, 1996. myeloid metaplasia. Leukemia 6:853, 1992.
280. Njoku OS, Lewis SM, Catovsky D, et al: Anaemia in myelofibrosis: Its value in progno- 314. Reilly JT, Snowden JA, Spearing RL, et al: Cytogenetic abnormalities and their prognos-
sis. Br J Haematol 54:79, 1983. tic significance in idiopathic myelofibrosis. Br J Haematol 98:96, 1997.
281. Howarth JE, Waters HM, Hyde K, Geary CG: Detection of erythroid hypoplasia in 315. Tefferi A, Mesa RA, Schroeder G, et al: Cytogenetic findings and their clinical relevance
myelofibrosis using erythrokinetic studies. J Clin Pathol 42:1250, 1989. in myelofibrosis with myeloid metaplasia. Br J Haematol 113:763, 2001.
282. Thiele J, Windecker R, Kvasnicka HM, et al: Erythropoiesis in primary (idiopathic) 316. Tefferi A, Meyer RG, Wyatt WA, et al: Comparison of peripheral blood interphase cyto-
osteomyelofibrosis. Am J Hematol 46:36, 1994. genetics with bone marrow karyotype analysis in myelofibrosis with myeloid metapla-
283. Bird GW, Wingham J, Richardson SG: Myelofibrosis, autoimmune haemolytic anaemia sia. Br J Haematol 115:316, 2001.
and Tn-polyagglutinability. Haematologica 18:99, 1985. 317. Sinclair EJ, Forrest EC, Reilly JT, et al: Fluorescence in situ hybridization analysis of
284. Kuo CY, VanVoolen GA, Morrison AN: Primary and secondary myelofibrosis: Its rela- 25 cases of idiopathic myelofibrosis and two cases of secondary idiopathic: Monoallelic
tionship to the PNH-like defect. Blood 40:875, 1972. loss of RB1, D13S319 and D13S25 loci associated with cytogenetic deletion and translo-
285. Veer A, Kosciolek BA, Bauman AW, et al: Acquired hemoglobin H disease in idiopathic cation involving 13q14. Br J Haematol 113:365, 2001.
myelofibrosis. Am J Hematol 6:199, 1979. 318. Reilly JT: Cytogenetic and molecular genetic aspects of idiopathic myelofibrosis. Acta
286. Barosi G, Baraldi A, Cassola M, et al: Red cell aplasia in myelofibrosis with myeloid Haematol 108:113, 2002.
metaplasia. Cancer 52:1290, 1983. 319. Andrieux J, Demory JL, Morel P, et al: Frequency of structural abnormalities of the
287. Silverstein MN, Elveback LR: Leukocyte alkaline phosphatase in agnogenic myeloid long arm of chromosome 12 in myelofibrosis with myeloid metaplasia. Cancer Genet
metaplasia. Am J Clin Pathol 61:307, 1974. Cytogenet 137:68, 2002.
288. Douer D, Fabian I, Cline MJ: Circulation pluripotent haemopoietic cells in patients 320. Dingli D, Grand FH, Mahaffey V, et al: Der(6)t(1;6)(q21–23;p21.3): A specific cytoge-
with myeloproliferative disorders. Br J Haematol 54:373, 1983. netic abnormality in myelofibrosis with myeloid metaplasia. Br J Haematol 130:229, 2005.
289. Barosi G, Viarengo G, Pecci A, et al: Diagnostic and clinical relevance of the number 321. Forrester RH, Louro JM: Philadelphia chromosome abnormality in agnogenic myeloid
of circulating CD34+ cells in myelofibrosis with myeloid metaplasia. Blood 98:3249, metaplasia. Ann Intern Med 64:622, 1966.
2001. 322. Gupta V, Hari P, Hoffman R. Allogeneic hematopoietic cell transplantation for myelofi-
290. Partanen S, Ruutu T, Vuopio P: Circulating haematopoietic progenitors in myelofibro- brosis in the era of JAK inhibitors. Blood 120:1367, 2012.
sis. Scand J Haematol 29:325, 1982. 323. Weda F, Takashima T, Suzuki M, Kadoya M: MR diagnosis of myelofibrosis. Radiat Med
291. Wang JC, Cheung CP, Ahmed F, et al: Circulating granulocyte and macrophage progen- 12:135, 1994.
itor cells in primary and secondary myelofibrosis. Br J Haematol 54:301, 1983. 324. Amano Y, Onda M, Amano M, Kumazaki T: Magnetic resonance imaging of myelofi-
292. Kornberg A, Fibach E, Treves A, et al: Circulating erythroid progenitors in patients with brosis. STIR and gadolinium-enhanced MR images. Clin Imaging 21:264, 1997.
“spent” polycythaemia vera and myelofibrosis with myeloid metaplasia. Br J Haematol 325. Schirrmeister H, Bommer M, Buck A, Reske SN: The bone scan ion osteosclerosis.
52:573, 1982. J Bone Miner Res 16:2361, 2001.
293. Colovi MD, Wiernik PH, Jankovi GM, et al: Circulating haematopoietic progenitor 326. Spanos G, Narasimhan P, Rosner F. Hypocholesterolemia in myelofibrosis. JAMA
cells in primary and secondary myelofibrosis: Relation to collagen and reticulin fibrosis. 245:235, 1981.
Eur J Haematol 62:155, 1999. 327. Cervantes F, Pereira A, Esteve J, et al: Identification of “short-lived” and “long-lived”
294. Tinggaard-Pedersen N, Laursen B: Megakaryocytes in cubital venous blood in patients patients at presentation of idiopathic myelofibrosis. Br J Haematol 97:635, 1997.
with chronic myeloproliferative diseases. Scand J Haematol 30:50, 1983. 328. Barosi G, Rosti V, Bonetti E, et al: Evidence that prefibrotic myelofibrosis is aligned
295. Cervantes F, Hernandez-Boluda JC, Villamor N, et al: Assessment of peripheral blood along a clinical and biological continuum featuring primary myelofibrosis. PLoS One
lymphocyte subsets in idiopathic myelofibrosis. Eur J Haematol 65:104, 2000. 7:e35631, 2012.
296. Marquetty C, Labro-Bryskier MT, Perianin A, et al: Impaired metabolic activity of 329. Gilbert HS, Ginsberg H, Fagerstrom R, Brown WV: Characterization of hypocholester-
phagocytosis neutrophils in agnogenic osteomyelofibrosis with splenomegaly. Am J olemia in myeloproliferative diseases. Am J Med 71:595, 1981.
Med 16:243, 1984. 330. Naggar L, Jaeger P, Burckhardt P, et al: Hypocalcemia and myelofibrosis: An unrecog-
297. Perianin A, Labro-Bryskier MT, Marquetty C, et al: Glutathione reductase and nitrob- nized association. Schweiz Med Wochenschr 116:1771, 1986.
lue tetrazolium reduction deficiencies in neutrophils of patients with primary idio- 331. Voss A, Schmidt K, Hasselbalch H, Junker P: Hypercalcemia in idiopathic myelofibro-
pathic myelofibrosis. Clin Exp Immunol 57:244, 1984. sis. Am J Hematol 39:231, 1992.
298. Briard D, Brouty-Boyé D, Giron-Michel J, et al: Impaired NK cell differentiation of 332. Wang JC, Chen C, Lou LH, Mora M: Blood thrombopoietin, IL-6 and IL-11 levels in
blood-derived CD34+ progenitors from patients with myeloid metaplasia with myel- patients with agnogenic myeloid metaplasia. Leukemia 11:1827, 1997.
ofibrosis. Clin Immunol 106:201, 2003. 333. Elliott MA, Yoon SY, Kao P, et al: Simultaneous measurement of serum thrombopoie-
299. Murphy S, Davis JL, Walsh PN, et al: Template bleeding time and clinical hemorrhage tin and expression of megakaryocyte c-MPL with clinical and laboratory correlates for
in myeloproliferative disease. Arch Intern Med 138:1251, 1978. myelofibrosis with myeloid metaplasia. Eur J Haematol 68:175, 2002.
300. Malpass TW, Savage B, Hanson SR, et al: Correlation between bleeding time and deple- 334. Wang JC, Hashmi G: Elevated thrombopoietin levels in patients with myelofibrosis may
tion of platelet dense granule ADP in patients with myelodysplastic and myeloprolifer- not be due to enhanced production of thrombopoietin by bone marrow. Leuk Res 27:13,
ative disorders. J Lab Clin Med 103:894, 1984. 2003.
301. Cunietti E, Gandini R, Marcaro G, et al: Defective platelet aggregation and increased 335. Wang J, Wang A: Plasma soluble interleukin-2 receptor in patients with primary myel-
platelet turnover in patients with myelofibrosis and other myeloproliferative diseases. ofibrosis. Br J Haematol 86:180, 1994.
Scand J Haematol 26:339, 1981. 336. Di Raimondo F, Azzaro MP, Palumbo GA, et al: Elevated vascular endothelial growth
302. Schafer AL: Deficiency of platelet lipoxygenase activity in myeloproliferative disorders. factor (VEGF) serum levels in idiopathic myelofibrosis. Leukemia 15:976, 2001.
N Engl J Med 306:381, 1982. 337. Dekmezian R, Kantarjian HM, Heating MJ, et al: The relevance of reticulin stain-
303. Shafer AL: Bleeding and thrombosis in the myeloproliferative disorders. Blood 64:1, 1984. measured fibrosis at diagnosis in chronic myelogenous leukemia. Cancer 59:1739, 1987.
304. Barbui T, Cortelazzo S, Viero P, et al: Thrombohaemorrhagic complications in 101 cases 338. Steensma DP, Hanson C, Letendre L, Teffari A: Myelodysplasia with fibrosis: A distinct
of myeloproliferative disorders: Relationship to platelet number and function. Eur J entity? Leuk Res 25:829, 2001.
Cancer Clin Oncol 19:1593, 1983. 339. Thiele J, Zankovich R, Steinberg T, et al: Primary (essential) thrombocythemia versus
305. Thiele J, Lorenzen J, Manich B, et al: Apoptosis (programmed cell death) in idiopathic initial hyperplastic stages of agnogenic myeloid metaplasia with thrombocytosis. Acta
(primary) osteo-/myelofibrosis. Acta Haematol 97:137, 1997. Haematol 81:192, 1989.

Kaushansky_chapter 86_p1319-1340.indd 1336 9/18/15 10:24 AM